8-K 1 a15-16423_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): July 28, 2015

 

 

Corium International, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-36375

 

38-3230774

(State or other jurisdiction of
incorporation or organization)

 

(Commission File Number)

 

(I.R.S. Employer
Identification Number)

 

235 Constitution Drive,
Menlo Park, California

 

94025

(Address of Principal Executive Offices)

 

(Zip Code)

 

(650) 298-8255
(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 7.01. Regulation FD.

 

On July 28, 2015, Corium International, Inc. (the “Company”) issued a press release announcing topline results from its Phase 2a study of Transdermal MicroCor PTH.  A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.  The Company will discuss these results further on its third fiscal quarter earnings conference call scheduled at 4:30 p.m. Eastern time on July 29, 2015.  A copy of the related presentation materials that the Company intends to provide to investors on the conference call are furnished as Exhibit 99.2 to this report and are incorporated herein by reference.  These presentation materials also are posted under the “Investors” section on the Company’s website at www.coriumgroup.com. The Company does not undertake to update these presentation materials.

 

The information furnished with this report, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press release dated July 28, 2015.

 

 

 

99.2

 

Presentation materials for conference call on July 29, 2015.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CORIUM INTERNATIONAL, INC.

 

 

Date: July 28, 2015

By:

/s/ Peter D. Staple

 

 

Peter D. Staple

 

 

Chief Executive Officer

 

3


 

INDEX TO EXHIBITS

 

Exhibit
Number

 

Description of Exhibit

 

 

 

99.1

 

Press release dated July 28, 2015.

 

 

 

99.2

 

Presentation materials for conference call on July 29, 2015.

 

4